Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by Isthmus Partners LLC

Isthmus Partners LLC lifted its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS) by 8.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 12,227 shares of the medical research company’s stock after buying an additional 1,000 shares during the period. Isthmus Partners LLC’s holdings in Exact Sciences were worth $687,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the stock. Huntington National Bank raised its holdings in shares of Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 352 shares during the period. RPg Family Wealth Advisory LLC bought a new stake in Exact Sciences during the third quarter valued at about $34,000. Capital Performance Advisors LLP acquired a new stake in shares of Exact Sciences in the third quarter worth $35,000. Asset Planning Inc bought a new position in Exact Sciences during the fourth quarter valued at about $40,000. Finally, Modus Advisors LLC acquired a new position in shares of Exact Sciences in the 4th quarter valued at $43,000. Institutional investors and hedge funds own 88.82% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have commented on EXAS shares. Scotiabank boosted their price objective on Exact Sciences from $70.00 to $73.00 and gave the stock a “sector outperform” rating in a research note on Monday, February 24th. TD Cowen upped their price objective on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a report on Tuesday, November 26th. Piper Sandler reduced their price target on shares of Exact Sciences from $75.00 to $70.00 and set an “overweight” rating on the stock in a research report on Wednesday, February 26th. William Blair restated an “outperform” rating on shares of Exact Sciences in a report on Thursday, February 20th. Finally, BTIG Research raised their target price on shares of Exact Sciences from $65.00 to $75.00 and gave the company a “buy” rating in a research note on Tuesday, November 26th. One equities research analyst has rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat, Exact Sciences presently has an average rating of “Moderate Buy” and an average target price of $71.94.

Exact Sciences Trading Up 0.9 %

Shares of EXAS stock opened at $47.06 on Monday. The stock has a market capitalization of $8.74 billion, a PE ratio of -8.45 and a beta of 1.25. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.15 and a quick ratio of 1.93. The business has a 50-day moving average of $52.88 and a 200 day moving average of $59.35. Exact Sciences Co. has a 1-year low of $40.62 and a 1-year high of $79.62.

Exact Sciences (NASDAQ:EXAS) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to analysts’ expectations of $701.45 million. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. As a group, sell-side analysts anticipate that Exact Sciences Co. will post -0.58 earnings per share for the current year.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.